These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12409734)

  • 1. T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev.
    MacGregor RR; Ginsberg R; Ugen KE; Baine Y; Kang CU; Tu XM; Higgins T; Weiner DB; Boyer JD
    AIDS; 2002 Nov; 16(16):2137-43. PubMed ID: 12409734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine.
    Blazevic V; Männik A; Malm M; Sikut R; Valtavaara M; Toots U; Ustav M; Krohn K
    AIDS Res Hum Retroviruses; 2006 Jul; 22(7):667-77. PubMed ID: 16831091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic T-lymphocyte induction in asymptomatic HIV-1-infected patients immunized with Retrovector-transduced autologous fibroblasts expressing HIV-1IIIB Env/Rev proteins.
    Ziegner UH; Peters G; Jolly DJ; Mento SJ; Galpin J; Prussak CE; Barber JR; Hartnett DE; Bohart C; Klump W
    AIDS; 1995 Jan; 9(1):43-50. PubMed ID: 7893440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins.
    Laube LS; Burrascano M; Dejesus CE; Howard BD; Johnson MA; Lee WT; Lynn AE; Peters G; Ronlov GS; Townsend KS
    Hum Gene Ther; 1994 Jul; 5(7):853-62. PubMed ID: 7981310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines.
    Boyer JD; Cohen AD; Vogt S; Schumann K; Nath B; Ahn L; Lacy K; Bagarazzi ML; Higgins TJ; Baine Y; Ciccarelli RB; Ginsberg RS; MacGregor RR; Weiner DB
    J Infect Dis; 2000 Feb; 181(2):476-83. PubMed ID: 10669329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
    Shiver JW; Perry HC; Davies ME; Freed DC; Liu MA
    Ann N Y Acad Sci; 1995 Nov; 772():198-208. PubMed ID: 8546393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity testing of a novel engineered HIV-1 envelope gp140 DNA vaccine construct.
    Kumar S; Yan J; Muthumani K; Ramanathan MP; Yoon H; Pavlakis GN; Felber BK; Sidhu M; Boyer JD; Weiner DB
    DNA Cell Biol; 2006 Jul; 25(7):383-92. PubMed ID: 16848679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage inflammatory protein-1alpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1.
    Lu Y; Xin KQ; Hamajima K; Tsuji T; Aoki I; Yang J; Sasaki S; Fukushima J; Yoshimura T; Toda S; Okada E; Okuda K
    Clin Exp Immunol; 1999 Feb; 115(2):335-41. PubMed ID: 9933462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo.
    Muthumani K; Zhang D; Dayes NS; Hwang DS; Calarota SA; Choo AY; Boyer JD; Weiner DB
    Virology; 2003 Sep; 314(1):134-46. PubMed ID: 14517067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
    Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
    Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
    Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
    PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses.
    Storcksdieck genannt Bonsmann M; Niezold T; Hannaman D; Überla K; Tenbusch M
    Vaccine; 2016 Apr; 34(15):1744-51. PubMed ID: 26945099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data.
    MacGregor RR; Boyer JD; Ciccarelli RB; Ginsberg RS; Weiner DB
    J Infect Dis; 2000 Jan; 181(1):406. PubMed ID: 10608800
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
    Hulot SL; Korber B; Giorgi EE; Vandergrift N; Saunders KO; Balachandran H; Mach LV; Lifton MA; Pantaleo G; Tartaglia J; Phogat S; Jacobs B; Kibler K; Perdiguero B; Gomez CE; Esteban M; Rosati M; Felber BK; Pavlakis GN; Parks R; Lloyd K; Sutherland L; Scearce R; Letvin NL; Seaman MS; Alam SM; Montefiori D; Liao HX; Haynes BF; Santra S
    J Virol; 2015 Jun; 89(12):6462-80. PubMed ID: 25855741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.
    Hammond SA; Bollinger RC; Stanhope PE; Quinn TC; Schwartz D; Clements ML; Siliciano RF
    J Exp Med; 1992 Dec; 176(6):1531-42. PubMed ID: 1460417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1.
    Wilson CC; McKinney D; Anders M; MaWhinney S; Forster J; Crimi C; Southwood S; Sette A; Chesnut R; Newman MJ; Livingston BD
    J Immunol; 2003 Nov; 171(10):5611-23. PubMed ID: 14607970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine.
    Gahery H; Daniel N; Charmeteau B; Ourth L; Jackson A; Andrieu M; Choppin J; Salmon D; Pialoux G; Guillet JG
    AIDS Res Hum Retroviruses; 2006 Jul; 22(7):684-94. PubMed ID: 16831093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects.
    Baden LR; Blattner WA; Morgan C; Huang Y; Defawe OD; Sobieszczyk ME; Kochar N; Tomaras GD; McElrath MJ; Russell N; Brandariz K; Cardinali M; Graham BS; Barouch DH; Dolin R;
    J Infect Dis; 2011 Nov; 204(10):1541-9. PubMed ID: 21940420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.
    zur Megede J; Chen MC; Doe B; Schaefer M; Greer CE; Selby M; Otten GR; Barnett SW
    J Virol; 2000 Mar; 74(6):2628-35. PubMed ID: 10684277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen.
    Weaver EA; Lu Z; Camacho ZT; Moukdar F; Liao HX; Ma BJ; Muldoon M; Theiler J; Nabel GJ; Letvin NL; Korber BT; Hahn BH; Haynes BF; Gao F
    J Virol; 2006 Jul; 80(14):6745-56. PubMed ID: 16809280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.